China Traditional Chinese Medicine Holdings Co. Limited (HKG:0570)
Hong Kong · Delayed Price · Currency is HKD 1.820
+0.030 (1.68%)
At close: Mar 27, 2026
HKG:0570 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 14,745 | 16,510 | 18,122 | 14,304 | 19,053 | |
Revenue Growth (YoY) | -10.69% | -8.90% | 26.69% | -24.92% | 28.68% |
Cost of Revenue | 7,654 | 8,653 | 8,847 | 7,106 | 7,224 |
Gross Profit | 7,091 | 7,856 | 9,274 | 7,198 | 11,829 |
Selling, General & Admin | 6,070 | 6,477 | 7,447 | 5,549 | 8,556 |
Research & Development | 511.47 | 596.01 | 685.63 | 611.83 | 694.44 |
Other Operating Expenses | -142.05 | -74.24 | -216.48 | -147.74 | -146.05 |
Operating Expenses | 6,621 | 7,104 | 7,926 | 6,023 | 9,120 |
Operating Income | 470.34 | 751.9 | 1,349 | 1,175 | 2,709 |
Interest Expense | -99.13 | -171.54 | -199.05 | -220.7 | -222.03 |
Interest & Investment Income | 34.65 | 47.68 | 65.26 | 67.27 | 62.58 |
Earnings From Equity Investments | -0.2 | -0.95 | -3.7 | -3.48 | -10.75 |
Currency Exchange Gain (Loss) | -1.86 | 1.8 | -0.38 | -0.12 | 0.77 |
Other Non Operating Income (Expenses) | -31.49 | -0.85 | 0.79 | 0.83 | 1.33 |
EBT Excluding Unusual Items | 372.31 | 628.04 | 1,212 | 1,019 | 2,541 |
Impairment of Goodwill | -494.92 | -431.83 | - | -35.87 | -29.78 |
Gain (Loss) on Sale of Investments | - | 0.36 | - | - | - |
Gain (Loss) on Sale of Assets | -5.64 | -1.29 | 33.72 | 4.75 | 24.53 |
Asset Writedown | -239.99 | -32.18 | -20.77 | -147.53 | -15.51 |
Pretax Income | -368.23 | 163.11 | 1,225 | 840.11 | 2,520 |
Income Tax Expense | 89.86 | 142.34 | -171.54 | 119.14 | 396.86 |
Earnings From Continuing Operations | -458.09 | 20.77 | 1,396 | 720.97 | 2,123 |
Net Income to Company | -458.09 | 20.77 | 1,396 | 720.97 | 2,123 |
Minority Interest in Earnings | 116.02 | 33.3 | -110.87 | 43.52 | -190.57 |
Net Income | -342.07 | 54.07 | 1,285 | 764.49 | 1,933 |
Net Income to Common | -342.07 | 54.07 | 1,285 | 764.49 | 1,933 |
Net Income Growth | - | -95.79% | 68.11% | -60.45% | 16.21% |
Shares Outstanding (Basic) | 5,036 | 5,036 | 5,036 | 5,036 | 5,036 |
Shares Outstanding (Diluted) | 5,036 | 5,036 | 5,036 | 5,036 | 5,036 |
EPS (Basic) | -0.07 | 0.01 | 0.26 | 0.15 | 0.38 |
EPS (Diluted) | -0.07 | 0.01 | 0.26 | 0.15 | 0.38 |
EPS Growth | - | -95.79% | 68.11% | -60.45% | 16.21% |
Free Cash Flow | - | 2,072 | 684.88 | 568.58 | 8.94 |
Free Cash Flow Per Share | - | 0.41 | 0.14 | 0.11 | 0.00 |
Dividend Per Share | - | 0.003 | - | 0.045 | 0.114 |
Dividend Growth | - | - | - | -60.16% | - |
Gross Margin | 48.09% | 47.59% | 51.18% | 50.32% | 62.09% |
Operating Margin | 3.19% | 4.55% | 7.44% | 8.21% | 14.22% |
Profit Margin | -2.32% | 0.33% | 7.09% | 5.34% | 10.14% |
Free Cash Flow Margin | - | 12.55% | 3.78% | 3.98% | 0.05% |
EBITDA | 1,535 | 1,816 | 2,421 | 2,216 | 3,505 |
EBITDA Margin | 10.41% | 11.00% | 13.36% | 15.49% | 18.39% |
D&A For EBITDA | 1,064 | 1,064 | 1,072 | 1,041 | 795.72 |
EBIT | 470.34 | 751.9 | 1,349 | 1,175 | 2,709 |
EBIT Margin | 3.19% | 4.55% | 7.44% | 8.21% | 14.22% |
Effective Tax Rate | - | 87.27% | - | 14.18% | 15.75% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.